This article was originally published in The Gray Sheet
Executive SummaryGrosses about $14.2 mil. in private placement of 2.1 mil. special warrants at $6.80 each through agents Midland Walwyn Capital and ScotiaMcleod. The warrants are exercisable for 2.1 mil. shares of common stock "without additional consideration," the firm states. Net proceeds will be used for initial production, clinical trials and commercialization of the Ottawa, Ontario firm's HeartSaver fully implantable ventricular assist device ("The Gray Sheet" Dec. 23, 1996, I&W-10). Funds from the offering are anticipated to be "sufficient to conduct the business of the company, including clinical trials in Canada, through the year 2000," World Heart states...
You may also be interested in...
ConMed's CFO Todd Garner told delegates at the Jefferies Healthcare conference that the company's orthopedic franchise is focused on its pipeline and meeting customer's needs. See what the CFO said about it here.
Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.
Correvio’s attempt to move vernakalant from 'clinical hold' to 'FDA approved' was a huge long shot. But the advisory committee vote – and looming FDA rejection – are another indication that real-world data is not a panacea.